Total Payments
$18,122
2019 Payments
$16,811
Companies
2
Transactions
16
Medicare Patients
1,794
Medicare Billing
$143,976
Payment Breakdown by Category
Consulting$15,530 (85.7%)
Research$1,311 (7.2%)
Travel$915.94 (5.1%)
Food & Beverage$364.99 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,530 | 2 | 85.7% |
| Unspecified | $1,311 | 3 | 7.2% |
| Travel and Lodging | $915.94 | 4 | 5.1% |
| Food and Beverage | $364.99 | 7 | 2.0% |
Payments by Type
General
$16,811
13 transactions
Research
$1,311
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16,811 | 13 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $1,311 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $16,811 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,811) |
| 2017 | $1,311 | 3 | Regeneron Pharmaceuticals, Inc. ($1,311) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/23/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $5,450.00 | General |
| Category: RESPIRATORY | ||||||
| 08/23/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 08/23/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $402.31 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $233.63 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $37.50 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $37.50 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $10,080.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: RESPIRATORY | ||||||
| 04/08/2017 | Regeneron Pharmaceuticals, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | — | In-kind items and services | $798.55 | Research |
| Study: An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/08/2017 | Regeneron Pharmaceuticals, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | — | In-kind items and services | $313.95 | Research |
| Study: An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/08/2017 | Regeneron Pharmaceuticals, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | — | In-kind items and services | $198.41 | Research |
| Study: An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,311 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 464 | 653 | $229,375 | $39,061 |
| 2022 | 9 | 542 | 776 | $239,708 | $42,295 |
| 2021 | 8 | 423 | 630 | $185,016 | $36,665 |
| 2020 | 7 | 365 | 518 | $145,346 | $25,954 |
Total Patients
1,794
Total Services
2,577
Medicare Billing
$143,976
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 120 | $65,238 | $11,575 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 108 | 120 | $46,356 | $7,840 | 16.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $22,504 | $4,006 | 17.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 37 | 38 | $19,402 | $3,374 | 17.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 37 | 38 | $17,510 | $3,192 | 18.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 60 | 66 | $21,186 | $2,941 | 13.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 14 | 15 | $11,287 | $2,318 | 20.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $13,765 | $2,129 | 15.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 37 | 187 | $9,163 | $1,087 | 11.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 11 | 13 | $2,964 | $600.97 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 112 | 126 | $67,308 | $12,863 | 19.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 140 | 147 | $55,515 | $9,689 | 17.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 90 | 99 | $31,779 | $5,096 | 16.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 44 | 49 | $24,380 | $4,256 | 17.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 44 | 45 | $20,430 | $3,663 | 17.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $13,816 | $2,654 | 19.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 21 | 21 | $9,996 | $1,778 | 17.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 61 | 259 | $12,691 | $1,642 | 12.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 11 | 11 | $3,793 | $652.14 | 17.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 106 | 127 | $59,960 | $12,909 | 21.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 115 | 131 | $44,025 | $9,687 | 22.0% |
| 17000 | Destruction of skin growth | Office | 2021 | 63 | 71 | $22,791 | $3,657 | 16.0% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 30 | 30 | $14,694 | $2,914 | 19.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $12,434 | $2,401 | 19.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 25 | 25 | $11,320 | $1,933 | 17.1% |
About Gideon Smith, MD PHD
Gideon Smith, MD PHD is a Dermatology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1649433152.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gideon Smith, MD PHD has received a total of $18,122 in payments from pharmaceutical and medical device companies, with $16,811 received in 2019. These payments were reported across 16 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($15,530).
As a Medicare-enrolled provider, Smith has provided services to 1,794 Medicare beneficiaries, totaling 2,577 services with total Medicare billing of $143,976. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Boston, MA
- Active Since 07/03/2008
- Last Updated 09/18/2019
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1649433152
Products in Payments
- OFEV (Drug) $16,811
- DUPIXENT DUPILUMAB INJECTION (Biological) $1,311
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Boston
Dr. Alexandra Kimball, Md Mph, MD MPH
Dermatology — Payments: $649,180
Dermatology $649,180
Dr. Maryanne Senna, M.d, M.D
Dermatology — Payments: $393,215
Dermatology $393,215
Brian Hibler
Dermatology — Payments: $324,366
Dermatology $324,366
Dr. Emmy Graber, M.d, M.D
Dermatology — Payments: $282,461
Dermatology $282,461
Dr. Mathew Avram, Md, MD
Dermatology — Payments: $228,216
Dermatology $228,216
Ruth Ann Vleugels, Md, MD
Dermatology — Payments: $194,613
Dermatology $194,613